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Abstract
Background: Large-scale screening methods are widely used to reveal cancer-specific DNA
methylation markers. We previously identified non-satellite 3.3-kb repeats associated with
facioscapulohumeral muscular dystrophy (FSHD) as hypermethylated in cervical cancer in genome-
wide screening. To determine whether hypermethylation of 3.3-kb repeats is a tumor-specific
event and to evaluate frequency of this event in tumors, we investigated the 3.3-kb repeat
methylation status in human papilloma virus (HPV)-positive cervical tumors, cancer cell lines, and
normal cervical tissues. Open reading frames encoding DUX family proteins are contained within
some 3.3-kb repeat units. The DUX mRNA expression profile was also studied in these tissues.
Methods: The methylation status of 3.3-kb repeats was evaluated by Southern blot hybridization
and bisulfite genomic sequencing. The expression of DUX mRNA was analyzed by RT-PCR and
specificity of PCR products was confirmed by sequencing analysis.
Results: Hypermethylation of 3.3-kb repeats relative to normal tissues was revealed for the first
time in more than 50% (18/34) of cervical tumors and in 4 HPV-positive cervical cancer cell lines.
Hypermethylation of 3.3-kb repeats was observed in tumors concurrently with or independently
of hypomethylation of classical satellite 2 sequences (Sat2) that were hypomethylated in 75% (15/
20) of cervical tumors. We have revealed the presence of transcripts highly homologous to DUX4
and DUX10 genes in normal tissues and down-regulation of transcripts in 68% of tumors with and
without 3.3-kb repeats hypermethylation.
Conclusion: Our results demonstrate that hypermethylation rather than hypomethylation of 3.3-
kb repeats is the predominant event in HPV-associated cervical cancer and provide new insight into
the epigenetic changes of repetitive DNA elements in carcinogenesis.
Background
DNA methylation plays an important role in the mainte-
nance of the gene expression program and genome stabil-
ity. Tumor cells are characterized by a paradoxical change
in DNA methylation pattern: global DNA demethylation
and local hypo- and hypermethylation of gene regulatory
regions that result in transcriptional activation of onco-
genes and inactivation of tumor suppressors. Current
Published: 27 May 2009
BMC Medical Genomics 2009, 2:30 doi:10.1186/1755-8794-2-30
Received: 18 December 2008
Accepted: 27 May 2009
This article is available from: http://www.biomedcentral.com/1755-8794/2/30
© 2009 Katargin et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
BMC Medical Genomics 2009, 2:30 http://www.biomedcentral.com/1755-8794/2/30opinion is that the targets for aberrant demethylation in
tumors are represented by DNA sequences that are meth-
ylated in normal tissues. Repetitive elements are consid-
ered among such DNA sequences. Frequent
hypomethylation of repetitive elements is observed in
diverse human cancers and is thought to largely account
for genomic instability [1-3].
Cervical carcinomas are the second most frequent type of
cancer in women. Infection with high risk type human
papilloma viruses (HR-HPV) is the main risk factor for
cervical cancer [4]. HR-HPV infections are extremely wide-
spread throughout the world, but malignant transforma-
tion is a rare consequence of the infection. The
progression from precursor intraepithelial lesions to cervi-
cal carcinomas is accompanied by additional genetic and
epigenetic changes that have not been fully characterized.
A low overall m5C content compared to normal cervical
tissue was demonstrated in cervical cancer, although the
methylation status has not been studied in any repetitive
elements except LINE-1 [5,6].
We previously conducted a genome-wide differential
analysis of DNA methylation in cervical cancer and nor-
mal tissues using methylation-sensitive arbitrarily primed
PCR [7] and identified CpG islands located within 3.3-kb
repeats as hypermethylated in tumors.
Members of the 3.3-kb repeat family reside in the subtelo-
meric regions of chromosomes 4 and 10 as tandemly
arranged polymorphic arrays containing from 11 to 100
monomers. In addition, they are present on the short
arms of all acrocentric chromosomes as interspersed
repeats [8-11]. The subtelomeric region 4q35 named
D4Z4 receives more attention because of its association
with facioscapulohumeral muscular dystrophy (FSHD),
an autosomal dominant disorder linked to partial dele-
tion of the D4Z4 repeat array. At least one sequenced copy
of D4Z4 contains a single-exon open reading frame (ORF)
and an upstream region that can function as a promoter
in reporter assays [12]. The ORF encodes a polypeptide
called DUX4 that has a high level of similarity to the
paired-type homeodomain proteins of families Pax and
Otx [13]. DUX4 and DUX4-related transcripts (DUX1, -3,
-4c -5, and -10) have been revealed in some human cells
[14-18]. DUX1 and DUX4 have the properties of a tran-
scription factor, and the products of exogenous transla-
tion of mRNAs of these genes localize to the cell nucleus
[12,15,19].
In many normal somatic tissues 3.3-kb repeats are mostly
but not completely methylated, and they are hypomethyl-
ated in glioblastomas, leukemia cell lines, tissues of
patients with FSHD and with DNA methyltransferase defi-
ciency syndrome ICF [20-24]. It has recently been shown
that 3.3-kb repeats in the D4Z4 array are hypomethylated
in some ovarian and Wilms tumors and are hypermethyl-
ated in other tumors of the same types relative to normal
tissues [25].
To determine whether hypermethylation of 3.3-kb repeats
is an event specific for HPV-positive cervical tumors and
to evaluate the frequency of this event, we examined the
methylation status of 3.3-kb repeats in tumors, cervical
cancer cell lines, and normal tissues. We have demon-
strated for the first time that more than 50% of cervical
cancers display hypermethylation of 3.3-kb repeats com-
pared to normal cervical tissues. Different regions within
the 3.3-kb monomer exhibit inter-individual variation in
the methylation patterns in normal tissues and different
susceptibility to hypermethylation in tumors. We have
shown that the 3.3-kb repeat hypermethylation can occur
in tumors concurrently with hypomethylation of classical
satellite 2 (Sat2) sequences that, according to many stud-
ies, are targets for demethylation in different tumor types
[1-3]. We also revealed the presence of transcripts highly
homologous to the DUX4 and 10 genes in normal uterine
cervical tissues and down-regulation of DUX-related tran-




Squamous cell carcinomas and adenocarcinomas of uter-
ine cervix and samples of adjacent normal tissues were
obtained from patients with FIGO stages I, II, and III of
the disease at the Blokhin Cancer Research Center. All
tumors were HPV16/18-positive, and E7 viral genes were
expressed in all of them according to PCR analysis [26].
Normal tissues of uterine cervix were obtained from
patients with uterine polyps or tumors. All tissues were
collected under the approval of the Institutional Review
Board of the Blokhin Cancer Research Center. Informed
consent was obtained from all patients. The study was
done in accordance with the principles outlined in the
Declaration of Helsinki.
Cell lines
The HPV-positive human cervical carcinoma cells HeLa,
SiHa, CaSki, and C4-I and the HPV-negative C-33A cell
line (American Type Culture Collection, USA) were main-
tained in DMEM supplemented with 10% FCS. Cells were
seeded at standard densities and treated with DNA meth-
yltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-dC;
Sigma, USA) for 3–4 days. The medium containing 5 μM
5-aza-dC was changed daily.
DNA and RNA extraction
DNAs and RNAs were isolated from frozen tissues or cells
by homogenization in 4.5 M guanidine isothiocyanate
and centrifugation through a cesium chloride cushion as
described previously [27].Page 2 of 11
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The bisulfite conversion reaction was carried out using an
EZ DNA Methylation Kit (Zymo Research, USA) according
to the manufacturer's instructions under the following con-
ditions: 15 cycles (30 s at 95°C and 15 min at 50°C). The
DNA samples were used for the PCR amplification by
JumpStart RedTaq DNA polymerase according to the man-
ufacturer's instructions (Sigma, USA). Three sets of 3.3-kb
repeat-specific primers corresponding to three regions on
the upper strand of bisulfite-modified DNA were used: (1)
Sq-1, sense GAA GGT AGG GAG GAA AAG (pos. 566) and
antisense ACT CAA CCT AAA AAT ATA CAA TCT (pos.
796); (2) Sq-2, sense TAT GAA GGG GTG GAG TTT G (pos.
1619) and antisense AAA TAC CAA TAA CCT AAA CCA AC
(pos. 1955); (3) Sq-3, sense AGT TTG GAG TTT TTG TAG-
TAG G (pos. 2942) and antisense CAA AAA TCC CAA ACC
AAT CAA CC (pos. 3192) [23]. Hereafter the positions of
primers are given according to the 3.3-kb monomer
sequence [GenBank: AF 117 653]. The PCR products were
cloned into pGEM-T Easy vector (Promega, USA) and used
for automated sequencing (ABI Prism 3100-Avant Genetic
Analyzer, Applied Biosystems, USA).
Southern blot analysis
DNA samples (10 μg) were digested overnight with meth-
ylation-sensitive restriction endonucleases (Fermentas,
Lithuania), separated in 1% agarose gel, transferred to a
nylon membrane (Zeta-Probe, Bio-Rad, USA), and hybrid-
ized with [32P]-labeled PCR DNA probes for 3.3-kb repeat
or Sat2-specific oligonucleotide TCG AGT CCA TTC GAT
GAT [28]. Hybridization was performed in 7% (w/v) SDS
(Sigma), 0.5 M sodium phosphate (pH 7.2), and 10 mM
EDTA at 65°C for the PCR probes or at 42°C for the Sat2
oligonucleotide. Some membranes were rehybridized with
the Sat2 oligonucleotide in 50% formamide at 42°C. The
membranes were washed 2 or 3 times in 2× SSPE/0.1% SDS
and in 0.1× SSPE/1% SDS at 55 and 42°C for the PCR and
Sat2 probes, respectively, and exposed to X-ray film at -
70°C. Intensities of hybridizing signals were determined
for paired normal and tumor samples or for each cell line
and three samples of healthy cervical tissues from patients
with non-cervical pathology in the same blot using the
Image-J 1.36b NIH software. The approximate extent of
hyper- or hypomethylation was calculated in that way: the
ratio of the high-molecular-weight hybridizing signal (>4.4
kb) to the total hybridization signal for each tumor (T) was
divided by the analogous ratio for matching normal tissue
(N). To calculate T/N for cell lines, the average from N for
three healthy cervical tissue samples was used.
Reverse transcription PCR
RT-PCR was carried with total cellular RNA treated with
DNase I (Invitrogen, USA) using reverse transcriptase
(Superscript II RNase H-, Invitrogen) according to the
manufacturer's instructions. DNA contamination was
controlled by conducting the same reaction without
reverse transcriptase for each RNA sample. PCR was per-
formed with the DUX4-specific primers (sense CCA CGG
AGA CTC GTT TGG AC, pos. 1863, and antisense CCT
GGA AAG CGA TCC TTC TCA, pos. 2141) under the fol-
lowing conditions: 94°C for 5 min; 35 cycles (94°C, 30 s;
64°C, 30 s; 72°C, 40 s), and at 72°C for 5 min. To control
the content of the initial total mRNA, PCRs were carried
out with the primers for GAPDH (sense ACC ACA GTC
CAT GCC ATC AC, antisense TCC ACC ACC CTG TTG
CTG TA) under the following conditions: 94°C, 5 min, 26
cycles (94°C, 30s; 58°C, 30s; 72°C, 1 min,) and 72°C for
5 min. After agarose gel electrophoresis, the PCR products
were visualized under ultraviolet light or transferred to a
membrane (Hybond-N+, Amersham Biosciences) and
probed with DUX4-specific [32P]-labeled internal oligo-
nucleotide TTG GTT TCA GAA TGA GAG GTC ACG (pos.
1996). Intensities of all bands were determined using the
Image-J 1.36b NIH software. DUX-specific signals were
normalized to GAPDH-specific signals in each sample,
and the ratios N/T were calculated. The average from five
healthy cervical tissue samples was used for unpaired
tumor samples. Threefold change in tumors relative to
normal tissues was taken into account.
Statistical analysis
Nonparametric Wilcoxon matched pairs test was used to
evaluate the methylation level differences between tumors
and adjacent normal tissues. Fisher's exact test (two
tailed) and χ-square test were used to compare frequen-
cies of hypermethylation in tumors and normal tissues
and portions of methylated CpG sites in different 3.3-kb
monomer regions, respectively. Differences were consid-
ered statistically significant when P-values were below
0.05. All statistical procedures were performed using STA-
TISTICA 6 software (StatSoft).
Results
Methylation pattern of 3.3-kb repeats in normal cervical 
tissues by bisulfite genomic sequencing
First, the 3.3-kb repeat methylation pattern was evaluated
in normal cervical tissues, which has not been reported
previously. Three regions within the 3.3-kb monomer
were selected for bisulfite genomic sequencing (Figure 1):
the 5' region (Sq-1); the middle region (Sq-2) around the
DUX-4 transcriptional start site that was described for a
single copy cloned from the 4q35 D4Z4 array of an FSHD
patient [12]; and the 3' region (Sq-3), which was shown to
be hypomethylated in glioblastomas [24]. Bisulfite
sequencing analysis can detect all closely homologous
3.3-kb copies from D4Z4 and other loci of the genome.
Normal cervical tissues from two non-cervical cancer
patients (Nc-1 and Nc-2) and two normal tissues adjacent
to cervical tumors (15-N and 5-N) were used (Figure 2).
The examined regions were unequally methylated in all
normal cervical tissues. The levels of methylation varied
from 23–61% for Sq-1 to 55–72% for Sq-2 and 49–59%Page 3 of 11
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nificantly less methylated compared to the Sq-2 or Sq-3
regions (P ≤ 10-4). In addition, significant interindividual
variations in the 3.3-kb repeat methylation patterns were
revealed. Normal tissues could differ from one another in
the local methylation level (Nc-1, Nc-2, 5-N and 15-N, Sq-
1 regions, P ≤ 0.008; Nc-1 from 5-N and 15-N, Sq-2
regions, P < 10-3). Finally, these results demonstrated that
normal cervical tissues exhibited a considerable but
incomplete methylation of 3.3-kb repeats just as shown
previously for the 4q35 D4Z4 locus in other normal tis-
sues by Southern blot analysis [21].
Methylation status of 3.3-kb repeats in cervical tumors and 
cancer cell lines by bisulfite genomic sequencing
The changes in the 3.3-kb repeat methylation status in
tumors were evaluated relative to paired normal tissues
taking into account considerable interindividual variation
in the repeat methylation pattern. Sequencing analysis
demonstrated hypermethylation in two tumors relative to
adjacent normal tissues (Figure 2, 5-T and 15-T). It is of
interest that the levels of hypermethylation differed
among the three regions. The methylation levels of the
middle regions Sq-2 did not change substantially in either
tumor compared to adjacent tissues (P > 0.05). The Sq-3
regions exhibited moderate but statistically significant lev-
els of hypermethylation in both tumors (P ≤ 0.006). At
the same time, a more strong increase in the Sq-1 region
methylation levels (1.6 and 2 times) was seen in two
tumors compared to matched normal tissues (P ≤ 3 × 10-
4). The strongest level of hypermethylation (87%) was
revealed in the Sq-1 region in HPV-positive cervical cancer
cell line SiHa. Surprisingly, all three regions exhibited
hypomethylation in HPV-negative cervical cancer cell line
C-33A compared to all other samples examined. The local
susceptibility to demethylation also varied (17%, 43%,
and 23% of methylated CpG sites for Sq-1, Sq-2, and Sq-
3 regions, respectively). These findings demonstrate that
the Sq-1 region is more susceptible to changes in the
methylation status than other regions and suggest that the
changes in methylation status of 3.3-kb repeats in cancer
cells may be sequence-specific.
Frequency of hypermethylation of 3.3-kb repeats in 
cervical HPV-positive carcinomas
The frequency of hyper- or hypomethylation of 3.3-kb
repeats in cervical HPV-positive carcinomas was studied by
Southern blot analysis of 34 paired samples using the frag-
ment of the 5' end of the 3.3-kb monomer as a hybridiza-
tion probe and NaeI methylation-sensitive restriction
endonuclease (Figure 3). Eleven NaeI sites reside within the
3.3-kb monomer including two sites located within the Sq-
1 region (Figure 1). This analysis shows the overall methyl-
ation status of all copies of the repeats. The methylation lev-
els in tumors were compared to those in nonmalignant
cervical tissues of the same patient taking into account indi-
vidual variations of methylation patterns of 3.3-kb repeats.
Indeed, the percentage of undigested DNA (high-molecu-
lar-weight fragments > 4.4 kb) of normal tissues from differ-
ent individuals substantially varied, confirming
interindividual distinctions in the 3.3-kb repeat methyla-
tion level revealed by sequencing analysis (Figure 3A, 44 to
66% in the same blot). Hypermethylation of 3.3-kb repeats
was revealed in 18 out of 34 (53%) carcinomas compared
to adjacent normal tissues (Figure 3C; P = 10-4). The sam-
ples with low (15-T) and middle (5-T) levels of hypermeth-
ylation determined by Southern blot exhibited clearly
detectible hypermethylation status by bisulfite genomic
sequencing (Figure 2). The hypermethylation of 3.3-kb
repeats was shown also in HPV-positive line SiHa by both
Southern blot and sequencing analysis, and both tech-
niques demonstrated the 3.3-kb repeat hypomethylation in
HPV-negative cell line C-33A. Thus, the results of both tech-
niques coincide with each other and sequencing data verify
the sensitivity of Southern blot for detecting differences in
DNA methylation. None of the 34 HPV-positive tumors dis-
played such low methylation level as HPV-negative cell line
C-33A did (Figure 3A and 3C). No correlation was found
between the 3.3-kb repeat methylation status and clinico-
pathological data (age, tumor stage, and histological grade
and type). This indicates that the 3.3-kb repeat hypermeth-
ylation may be an early event during cervical carcinogenesis.
Thus, these results demonstrate that hypermethylation
rather than hypomethylation of 3.3-kb repeats is a frequent
event in HPV-positive cervical carcinomas.
Diagram of a 3.3-kb monomerFigure 1
Diagram of a 3.3-kb monomer. Two squares denote double homeobox region. Sq-1, Sq-2, and Sq-3 mark the regions 
selected for sequencing analysis. The hybridization probes and RT-PCR primers are indicated by horizontal lines and arrows, 
respectively. The broken arrow indicates the position of DUX4 transcription start site. Vertical lines indicate NaeI sites.Page 4 of 11
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Methylation status of 3.3-kb repeats by sodium bisulfite sequencing in cervical tissues, tumors, and cell linesFigure 2
Methylation status of 3.3-kb repeats by sodium bisulfite sequencing in cervical tissues, tumors, and cell lines. 
Sq-1, Sq-2, and Sq-3 mark three regions of 3.3-kb monomer selected for sequencing. Each row of circles represents a cloned 
DNA molecule; closed circle, methylated CpG; open circle, unmethylated CpG; dot, CpG site lost from the consensus 
sequence due to mutations; cross, CpG site status was not determined. The percentage of methylated CpGs among all CpGs 
analyzed is given below each sample. Nc, normal cervix from non-cervical-cancer patients; T, tumor; N, tumor – tumor-adja-
cent normal tissue. Numbers of patients are indicated as in Figure 3C. Only P values below 0.05 are given (χ-square test).
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hypomethylation of satellite repeat Sat2 in cervical tumors 
and cancer cell lines
The high frequency of hypermethylation of 3.3-kb repeats
in cervical cancer has not been reported earlier. In order to
determine whether 3.3-kb repeat hypermethylation takes
place in HPV-positive cervical tumors along with the well-
known hypomethylation of different repeats in tumors,
the methylation status of Sat2 was analyzed by Southern
blot hybridization (Figure 3B and 3D). The Sat2 methyla-
tion status in normal and tumor cervical tissues was not
known. Here, no low-molecular-weight fragments (< 4.4
kb) were revealed by Southern blot analysis in normal cer-
vical tissues adjacent to tumors. This indicates that Sat2 is
highly methylated in normal cervix just as in other human
normal tissues. On the contrary, a large portion of the
hybridization signal was observed in the low-molecular-
weight fragments (< 4.4 kb) in tumors demonstrating
hypomethylation of Sat2. Sat2 hypomethylation was
revealed in 15 out of 20 (75%) tumors relative to normal
adjacent tissues and in 5 cancer cell lines examined (Fig-
ure 3D; P = 10-4). Hypermethylation of 3.3-kb repeats and
hypomethylation of Sat2 can coexist in the same tumor
(Figure 3D and Additional file 1). On the other hand, Sat2
hypomethylation was observed in the tumors in the
absence of 3.3-kb repeat hypermethylation indicating that
the changes in the methylation pattern of different repeats
are independent.
Expression of DUX genes by RT-PCR
The distribution of some DUX-related transcripts in nor-
mal and tumor cervical tissues was analyzed by RT-PCR
with DUX4-specific primers. The products of RT-PCR of
predicted size were revealed in normal uterine cervix and
in normal tissues adjacent to cervical tumors. (Figure 4,
Table 1). The expression levels in normal tissues were low
compared to that of a control gene, GAPDH. To reveal the
transcription suppression in tumors compared to normal
tissues, RT-PCR products were analyzed by Southern blot
hybridization with [32P]-labeled DUX4-specific oligonu-
cleotide. In 30 out of 44 (68.2%) cervical carcinomas the
[32P] RT-PCR bands were undetectable or faint compared
to normal tissues. Twenty four tumors had matched nor-
mal tissues and 20 tumors were compared to the average
from 5 healthy cervical tissue samples. The PCR products
were absent in 5 out of 24 (20.8%) normal tissues adja-
cent to cervical tumors with suppression of DUX tran-
scription. This indicates that interruption of DUX
transcription may be an early event in carcinogenesis. The
PCR products were also absent in 4 HPV-positive cancer
cell lines.
The specificity of PCR amplification was tested by cloning
the 299-bp RT-PCR products of C-33A cell lines and
sequencing of 11 such clones. All copies were highly
homologous to DUX4, DUX4c (100–94%), and DUX10
(99.7–89%). The cloned sequences were less similar to
DUX1-3 and DUX5 (84–90%). One third of the tran-
scripts had perfect ORFs. Thus, the transcripts revealed by
RT-PCR in cervical cells are highly homologous to DUX
family genes.
Analisis of methylation status of 3.3-kb and Sat2 repeats in HPV-positive cervical tumor by Southern blo  hybridizationFigure 3
Analisis of methylation status of 3.3-kb and Sat2 
repeats in HPV-positive cervical tumors by Southern 
blot hybridization. Nc, normal cervix from non-cervical-
cancer patients; T, tumor; N, tumor-adjacent normal tissue. 
Lines to the left of the panel are molecular mass markers 
(from top to bottom, 24.3, 9.4, 6.6, 4.4, 2.3, 2.0, and 0.5 kb). 
(A) Hybridization with the 3.3-kb repeat-specific probe, NaeI 
digests of DNAs. Numbers under the panels indicate the per-
centage of the high-molecular-weight hybridization signal 
(>4.4 kb) to the total hybridization signal for each track. (B) 
Hybridization with the Sat2-specfic oligonucleotide, BstBI 
digests of DNAs. (C) Hypermethylation of 3.3-kb repeats in 
tumors. (D) Hypomethylation of Sat2 in tumors. The aster-
isk and triangle indicate samples with hypermethylation and 
hypomethylation of 3.3-kb repeats, respectively; the circle – 
unchanged methylation status of 3.3-kb repeats.Page 6 of 11
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gene expression
The results of both 3.3-kb repeat methylation status and
DUX gene expression were available for 24 carcinomas
and matched normal tissue (Table 2). DUX mRNA expres-
sion was suppressed in 10 carcinomas with hypermethyl-
ation. Four highly methylated cell lines had no DUX
transcripts. The transcripts were revealed in only one can-
cer cell line with hypomethylated 3.3-kb repeats (C-33A).
Thus, there is a significant correlation between hyper-
methylation of 3.3-kb repeats and down-regulation of
DUX transcription. This indicates that methylation plays a
role in inactivation of DUX transcription. However, there
were 8 out of 18 (44%) tumors that had lost DUX tran-
scripts without change in methylation status compared to
nonmalignant tissues. These findings suggest that there
are other mechanisms besides DNA methylation underly-
ing the suppression of DUX expression.
Re-expression of DUX genes after treatment with 5-aza-
dC
Re-expression of DUX genes after 5-aza-dC treatment was
revealed in one out of four highly methylated cervical cell
lines, CaSki, which confirms both the role of methylation
in the expression control of DUX genes and the existence
of other mechanisms of DUX gene silencing (Figure 4).
Discussion
Prevalence of hypermethylation over hypomethylation of 
3.3-kb repeats in HPV-positive tumors
Demethylation at repeated DNA sequences is a common
hallmark of human cancers and can be used as a surrogate
marker of genome-wide methylation changes. [1-3]. We
have demonstrated that the 3.3-kb repetitive elements are
heavily but not completely methylated in normal cervical
tissues and subject to hypermethylation in more than
50% of HPV-positive cervical tumors and four cervical
cancer cell lines. It has been shown that 3.3-kb repeats are
hypomethylated in glioblastomas and leukemia cell lines;
they are hypomethylated in some portion of ovarian and
Wilms tumors but hypermethylated in another portion of
these tumors [23-25]. We observed strong hypomethyla-
tion of 3.3-kb repeats relative to normal cervical epithe-
lium only in HPV-negative cancer cell line and have
concluded that 3.3-kb repeat hypermethylation is the pre-
dominant event in cervical cancer. There were no HPV-
negative cervical tumors among our samples, and the
methylation status of 3.3-kb repeats in them remains to
be evaluated, but one cannot exclude that the prevalence
of the 3.3-kb repeat hypermethylation in cervical tumors
is related to HPV genome persistence. HR-HPVs induce
carcinomas by expressing viral oncogenes E6 and E7 [4].
E7 deregulates several cellular pathways. In particular, it
inactivates the retinoblastoma tumor suppressor protein
(Rb) [29]. In normal cells, Rb regulates DNA methyltrans-
ferase 1 (DNMT1) that maintains DNA methylation dur-
ing S phase of the cell cycle by at least two mechanisms.
Rb directly interacts with and modulates DNMT1 activity,
and Rb is required for proper cell cycle regulation of
Dnmt-1 transcription [30,31]. Oncogene E7 disrupts this
regulation, abolishing Rb; in addition, it directly interacts
with and activates DNMT1 [32]. It has been shown
recently that DNMT1 is necessary to maintain the 3.3-kb
repeat methylation [33]. The fine mechanisms responsi-
ble for changes of 3.3-kb repeat methylation status remain
to be clarified, but the persistence of E7 in HPV-positive
tumors likely ensures prevalence of hypermethylation
over hypomethylation of 3.3-kb repeats in contrast to
Analysis of DUX gene expression in cervical tumors and cell lines by RT-PCRFigure 4
Analysis of DUX gene expression in cervical tumors 
and cell lines by RT-PCR. Top row: Southern blot hybrid-
ization of PCR products with the DUX4-specific [32] P-
labeled oligonucleotide. Middle and bottom rows, electro-
phoregrams after ethidium bromide staining. GAPDH, a con-
trol for RNA stability and concentration. RT, reverse 
transcriptase; Nc, normal cervix from non-cervical-cancer 
patients; T, tumor; N, tumor-adjacent normal tissue. Patient 
numbers are as in figure 3.Page 7 of 11
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processes may take place. Other tandem repeats, NBL2,
have been found to be hypomethylated in some types of
cancer but hypermethylated in others [34,35]. Taken
together, these data bring up the question of tumor-type
specificity in epigenetic changes of repeats.
Sequence-specific 3.3-kb repeat methylation
We have demonstrated that different regions of the 3.3-kb
monomer were irregularly methylated in normal tissues
and were subject to hypermethylation independently
from one another in the same tumor. The 5' region (Sc-1)
was less methylated in normal tissues but more suscepti-
ble to both hypomethylation and hypermethylation in
tumor cells than other regions. Recently, the presence of a
hypermethylation-resistant region within the 3.3-kb
monomer was shown in ovarian and Wilms tumors [25].
This hypermethylation-resistant region is located only 70
and 100 nucleotides upstream from our Sq-2 region and
the TATA box, respectively. The Sq-2 region is noticeably
methylated in normal tissues, and its methylation level
showed no significant changes in tumors. Overall, at least
three subregions with different status and susceptibility to
hypermethylation have been found within the 5' half of
the 3.3-kb monomer [25] and the Sq1 and Sq2 regions.
Both hypomethylation and hypermethylation of different
CpG dinucleotides was shown in a short region of NBL2,
a tandem DNA repeat, in tumors [36].
Hence, these studies and our data demonstrate that
changes in the methylation status of genomic repeats in
tumors may be sequence-specific. This indicates that the
choice of the region to test may greatly influence conclu-
sions reached by studying the methylation status of DNA
repeats in cancer.
Different local susceptibility to methylation can be due to
the complex structure of the 3.3-kb monomer, which
includes several known sequence motifs: double home-
obox, LSau, and hhspm3 [8,37]. Several regulator
sequences have been found within these motifs. The 5'
region of the 3.3-kb element studied here (Sq-1) is about
200 bp downstream from the LSau motif (Figure 1). LSau
contains an exceptionally strong transcriptional enhancer
[38]. Our middle region of the 3.3-kb element (Sq-2)
includes a fragment of hhspm3. This region can function as
a promoter in reporter assays and includes a TATA box and
a transcription initiation site of DUX4 [12,16]. It has been
shown that the multiprotein complex containing the tran-
scription activator/repressor YY1 binds this region in HeLa
cells and represses transcription of genes located upstream
from D4Z4 [39]. The 3' end of the 3.3-kb element was
shown to have a strong activator in a reporter assay [40].
Our hypermethylation-susceptible Sq-3 region lies within
this fragment. It is possible that the interplay between the
system of DNA methylation and regulatory factors binding
these different regions determines their methylation levels
in normal tissues and their susceptibility to hypermethyla-
tion in tumors. It is also possible that tissue-specific regula-
tory factors determine tumor-type specificity in epigenetic
changes of 3.3-kb repeats discussed above.
Both Sat2 hypomethylation and 3.3-kb repeat 
hypermethylation in tumors
We observed hypomethylation of Sat2 in cervical tumors
along with hypermethylation of 3.3-kb repeats. It has
been shown that Sat2 hypomethylation is significantly
associated with global DNA hypomethylation in different
tumors [2,3]. Thus, hypermethylation of 3.3-kb repeats
does not interfere with the process of DNA hypomethyla-
Table 1: Frequency of down-regulation of expression of DUX-related genes in normal tissues and cervical carcinomas
Samples No. tested Down-regulation of mRNA
Normal cervical tissues 5 0
Adjacent to tumors nonmalignant cervical tissues 24 5 (20.8%)*
Tumors 44 30 (68.2%)
P = 0.003**
Cervical cancer cell lines 5 4
Down-regulation was defined as the ratio normal/tumor exhibiting at least threefold reduction of mRNA level in tumor or the absence of mRNA 
expression.
* Products of PCR were absent in adjacent normal tissue as well as matched tumor.
** Fisher's exact test
Table 2: Correlation between 3.3-kb repeats hypermethylation 
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site processes are not known. Both Sat2 and 3.3-kb repeats
are targets of DNMT3b, but only the latter is a target of
DNMT1 [28,33,41], which can explain the different
changes in their methylation status, in particular, in
tumors. In addition, different epigenetic fates of two
repeat types in the same tumor can be predetermined by
their chromatin structure in normal cells: Sat2 DNA
sequences reside in the centromere-adjacent heterochro-
matin, while 3.3-kb repeats within the D4Z4 array exhibit
unexpressed euchromatin-like features [2,42].
Hypomethylation of Sat2 was revealed in tumors with
and without hypermethylation of 3.3-kb repeats. The
absence of associations between changes of methylation
status of two types of DNA repeats confirms the independ-
ent role of DNA hypo- and hypermethylation in tumor
formation or progression.
Down-regulation of transcription of DUX-related genes in 
tumors
Transcriptional repression of DUX genes occurred in 68%
of cervical carcinomas by methylation and some other
mechanism. Proof of transcription of DUX genes in some
normal cells has been provided [14,17]. We demonstrated
that most normal cervical tissues showed clearly detectable,
albeit low, levels of transcription from 3.3-kb repeat ORFs.
Sequence analysis has demonstrated high homology of the
transcripts amplified using our primers to DUX4, DUX4c,
and DUX10 genes (89–100%), but not all transcripts have
perfect ORFs. Our findings are consistent with previous
studies that indicate that, in spite of hundreds of 3.3-kb
copies in the human genome, there are not so many tran-
scripts that could be translated into functional DUX pro-
teins [9,15,17]. Despite many investigations, it is still
unclear whether DUX proteins are expressed in normal tis-
sues. Currently, the evidence for the presence of a protein in
vivo has only been obtained for DUX4 and DUX1 genes.
Both proteins are expressed in human-derived rhabdomy-
osarcoma cell lines, and DUX4 is expressed in myoblasts of
FSHD patients [14-16]. No evidence for the presence of
DUX proteins in normal cells has yet been obtained. Sur-
prisingly, the DUX4 ORF was recently shown to be con-
served over 100 million years of evolution [43]. The
authors believe that the DUX4 ORF conservation was not
occasional but was selected, most likely, for the protein-
coding function. High frequency of DUX4 transcriptional
down-regulation in cervical tumors is an additional indi-
rect evidence for the putative protein-coding function of
3.3-kb repeats and an argument for further search for DUX
proteins in normal somatic and embryonic tissues.
A possible role of hypermethylation and transcriptional 
silencing of 3.3-kb repeats in cervical cancer
What is the role of hypermethylation and transcriptional
silencing of the 3.3-kb repeats in carcinogenesis consider-
ing low quantities of functional DUX proteins in normal
cells? Some biological functions of DUX proteins are now
known. The direct transcriptional target of the DUX4 pro-
tein has been identified. DUX 4 interacts in vitro with a cis-
element in the promoter region of paired-like homeodo-
main transcription factor 1 (PITX1) and activates expres-
sion of the endogenous PITX1 gene in myoblasts [16]. In
turn, PITX1 is a positive regulator of p53 and negative reg-
ulator of the RAS pathway [44,45]. In addition, DUX4 is a
proapoptotic protein, and its forced exogenous expression
in cell culture leads to cell death via apoptosis [15]. It is
likely that DUX4 might be an initial trigger of a cascade of
transcription factors regulating protooncogenes, tumor
suppressors, and proapoptotic genes. Low expression of
an initial transcription factor frequently occurs in embry-
onic differentiation. Thus, extremely low concentration of
DUX4 in normal cells is not surprising taking into consid-
eration its biological functions, and DUX4 silencing in
tumors might deregulate several pathways usually affected
in them.
An alternative view is that 3.3-kb repeats have a non-cod-
ing, regulatory function and play a role in the formation
and maintenance of heterochromatin in the subtelomeric
regions of chromosomes 4 and 10 or in the maintenance
of higher-order chromatin structure and regulation of
neighboring gene expression on the chromosomes in nor-
mal cells [38,39,46-48]. It was shown that the structure of
3.3-kb repeat chromatin in both 4q and 10q is similar to
that of unexpressed euchromatin rather than of constitu-
tive heterochromatin [25,42]. It remains to be established
whether the overall increase in the 3.3-kb repeat methyla-
tion level in tumors can have an influence on the hetero-
chromatinization of 3.3-kb repeats and/or changes of
higher-order chromatin structure and expression of neigh-
boring genes.
Conclusion
Our results demonstrate that hypermethylation rather
than hypomethylation of 3.3-kb repeats is a frequent
event in HPV-associated cervical cancer and show a more
complex pattern of changes in genome methylation in
cancer than previously thought.
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